Curtis G C, Cameron O G, Nesse R M
Am J Psychiatry. 1982 Aug;139(8):1043-6. doi: 10.1176/ajp.139.8.1043.
Reports that imipramine and phenelzine prevent panic attacks in agoraphobia suggest the possibility that agoraphobia and/or panic disorder might be a clinical manifestation of underlying depression. To test this hypothesis, dexamethasone suppression tests (DSTs) were performed in 10 patients meeting DSM-III criteria for agoraphobia with panic attacks, 6 for panic disorder, and 4 whose diagnosis could have been either panic disorder or agoraphobia except that another axis I disorder precluded such a diagnosis. Abnormal DSTs were observed in only 3 patients and appeared to be attributable to causes other than panic attacks or agoraphobia. The results suggest that panic attacks and endogenous depression are separate disorders and that the antipanic properties of imipramine and phenelzine are separate from their antidepressant actions.
有报告称丙咪嗪和苯乙肼可预防广场恐怖症中的惊恐发作，这提示广场恐怖症和/或惊恐障碍可能是潜在抑郁症的一种临床表现。为验证这一假设，对10名符合DSM-III标准的伴有惊恐发作的广场恐怖症患者、6名惊恐障碍患者以及4名诊断可能为惊恐障碍或广场恐怖症但因另一种轴I障碍而排除该诊断的患者进行了地塞米松抑制试验（DST）。仅在3名患者中观察到异常DST，且似乎可归因于惊恐发作或广场恐怖症以外的原因。结果表明惊恐发作和内源性抑郁症是不同的疾病，丙咪嗪和苯乙肼的抗惊恐特性与其抗抑郁作用是分开的。
